Viewing StudyNCT05740449

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 6:40 PM
Last Modification Date: 2024-10-26 @ 2:52 PM
Study NCT ID: NCT05740449
Status: WITHDRAWN
Last Update Posted: 2024-06-21
First Post: 2023-02-13
Brief Title: HEM-iSMART-A Decitabine Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Sponsor: Princess Maxima Center for Pediatric Oncology
Organization: Princess Maxima Center for Pediatric Oncology
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Acute Lymphoblastic Leukemia in Relapse
Lymphoblastic Lymphoma Precursor B-Lymphoblastic LymphomaLeukaemia Recurrent
Lymphoblastic Lymphoma Precursor T-Lymphoblastic LymphomaLeukaemia Recurrent
Lymphoblastic Lymphoma Precursor B-Lymphoblastic LymphomaLeukaemia Refractory
Lymphoblastic Lymphoma Precursor T-Lymphoblastic LymphomaLeukaemia Refractory
Keywords:
Name View
Young adults View
Acute lymphoblastic leukemia View
Lymphoblastic lymphoma View
Epigentic approach View
decitabine View
navitoclax View
venetoclax View
Relapse View
Refractory View
Children View
Adolescents View